Leukemia Research
Volume 33, Issue 11 , Pages 1448-1449 , November 2009

Translating genetic questions into clinical answers in acute myeloid leukemia

  • Sapana Vora

      Affiliations

    • Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, United States
    • ,
  • Nathan Ellis

      Affiliations

    • Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, United States
    • Department of Medicine, University of Chicago, Chicago, IL 60637, United States
    • ,
  • Kenan Onel

      Affiliations

    • Committee on Cancer Biology, University of Chicago, Chicago, IL 60637, United States
    • Department of Pediatrics, University of Chicago, Chicago, IL 60637, United States
    • University of Chicago Cancer Research Center, University of Chicago, Chicago, IL 60637, United States
    • Corresponding Author InformationCorresponding author at: Section of Hematology/Oncology, Department of Pediatrics, University of Chicago, 5841 S. Maryland Avenue, C-425, MC 4060, Chicago, IL 60637, United States. Tel.: +1 773 702 4919; fax: +1 773 702 9881.

Received 11 June 2009

References 

  1. Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer. 2003;39:1053–1060
  2. Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet. 2009;84:534–541
  3. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365
  4. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100
  5. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:2217–2224
  6. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer. 2006;119:1863–1868
  7. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18:377–385
  8. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:1602–1611
  9. Sousa H, Santos AM, Pinto D, Medeiros R. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007;20:731–741
  10. Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, et al. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis. 2007;28:1680–1686
  11. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602
  12. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res. 2005;65:9582–9587
  13. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 2006;43:531–533
  14. Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, et al. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008;112:741–749
  15. Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leukemia Res; in press.
  16. Phang BH, Linn YC, Li H, Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur J Cancer. 2008;44:760–766
  17. Knight JA, Skol AD, Shinde A, Hastings D, Walgren RA, Shao J, et al. A genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood; in press.

PII: S0145-2126(09)00295-1

doi: 10.1016/j.leukres.2009.06.018

Leukemia Research
Volume 33, Issue 11 , Pages 1448-1449 , November 2009

Article Tools